Beyond intrinsic epigenetic modulation, EZH2 inhibitors significantly enhance the efficacy of adoptive T cell therapies, such as CAR-T and TCR-T cells, in gynecological cancers. This evidence concerns the gene EZH2 and female reproductive organ cancer.